Muhammad Ashraf, Ph.D.

US Food and Drug Administration

Poster(s):

• (T1530-08-54) Critical Formulation Attributes of Naloxone Nasal Spray Products Affecting Nasal Permeation
  Tuesday, October 24, 2023

  3:30 PM – 4:30 PM ET

• (W1230-10-67) Development of In Vitro In Vivo Correlation for Establishing Clinically Relevant Dissolution Specifications of Lamotrigine ER Tablets
  Wednesday, October 25, 2023

  12:30 PM – 1:30 PM ET

• (T1530-09-61) Effect of Collagen Source on the In Vitro Performance of Collagen Implant
  Tuesday, October 24, 2023

  3:30 PM – 4:30 PM ET

• (T1230-08-55) Long-Term Stability of In-House Sunscreen Formulations
  Tuesday, October 24, 2023

  12:30 PM – 1:30 PM ET

• (W0930-08-52) Method Development for the Evaluation of Orally Inhaled Drug Products (OIDPs) containing Spray-Dried Phospholipid Porous Particles (PPPs)
  Wednesday, October 25, 2023

  9:30 AM – 10:30 AM ET

• (M1330-08-55) Understanding Release Mechanism and Development of Accelerated Release Tests for Long-Term Intrauterine Systems
  Monday, October 23, 2023

  1:30 PM – 2:30 PM ET